Scarica l'app Stockscreener
11.84
2.87%
-0.35
Dopo l'orario di chiusura:
11.70
-0.14
-1.18%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.19
Aprire:
$12.05
Volume 24 ore:
294.98K
Relative Volume:
1.45
Capitalizzazione di mercato:
$161.55M
Reddito:
-
Utile/perdita netta:
$-104.29M
Rapporto P/E:
-1.9626
EPS:
-6.0329
Flusso di cassa netto:
$-81.45M
1 W Prestazione:
-7.21%
1M Prestazione:
-16.03%
6M Prestazione:
-8.22%
1 anno Prestazione:
+35.78%
Intervallo 1D:
$11.73
$12.32
Intervallo di 1 settimana:
$11.73
$13.28
Portata 52W:
$5.062
$17.43
Immunic Inc Stock (IMUX) Company Profile
Nome
Immunic Inc
Settore
Industria
Telefono
(332) 255-9818
Indirizzo
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
11.84 | 166.33M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | Stifel | Buy |
| 2026-04-15 | Downgrade | D. Boral Capital | Buy → Hold |
| 2026-03-24 | Iniziato | Guggenheim | Buy |
| 2025-11-07 | Iniziato | Roth Capital | Buy |
| 2025-09-29 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-25 | Iniziato | William Blair | Outperform |
| 2024-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-27 | Iniziato | B. Riley Securities | Buy |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2021-04-15 | Iniziato | Aegis Capital | Buy |
| 2021-03-24 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-02 | Iniziato | SVB Leerink | Outperform |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-08-07 | Ripresa | ROTH Capital | Buy |
| 2020-07-20 | Iniziato | BMO Capital Markets | Outperform |
| 2020-06-05 | Iniziato | Wedbush | Outperform |
| 2020-05-11 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-25 | Iniziato | ROTH Capital | Buy |
| 2019-07-11 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Immunic Inc Borsa (IMUX) Ultime notizie
IMUX Reiterated by Wedbush -- Price Target Maintained at $45 - GuruFocus
Why Is Immunic (NASDAQ:IMUX) Advancing Its MS Drug Program? - Kalkine Media
Stifel reiterates Immunic stock rating on MS drug potential By Investing.com - Investing.com Canada
Stifel reiterates Immunic stock rating on MS drug potential - Investing.com
H.C. Wainwright reiterates Immunic stock rating on MS drug progress By Investing.com - Investing.com Canada
IMUX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $22 - GuruFocus
Immunic, Inc. R&D Day Transcript - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026 - TradingView
Immunic (NASDAQ: IMUX) plans Sept. 9 relapsing MS R&D webinar - Stock Titan
Immunic hosts RMS R&D Day webinar, presents vidofludimus calcium program and forward-looking plans - TradingView
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 - PR Newswire
Immunic Inc (NASDAQ: IMUX) Share Price, IMUX Stock News, IMUX Share Price & Updates - Kalkine
Immunic lines up three July investor events in Boston and SF - stocktitan.net
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Small cap wrap: Immunic, Midnight Sun Mining, Purepoint Uranium... - proactiveinvestors.com.au
Immunic to host virtual R&D day on relapsing MS ahead of Phase 3 trial results - Pluang
Immunic to host virtual relapsing MS R&D Day on September 9 - Yahoo Finance
EQS-News: Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026boerse.de - boerse.de
Immunic names Chitrang Davé chief data and digital officer - thepharmaletter.com
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer - Investing News Network
Immunic appoints Chitrang Davé as chief data and digital officer - Yahoo Finance
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating (NASDAQ:IMUX) - Seeking Alpha
Long term debt to total assets ratio of Immunic, Inc. – HAM:10V - TradingView
Discontinued operations of Immunic, Inc. – HAM:10V - TradingView
Wedbush initiates Immunic stock with Outperform rating By Investing.com - Investing.com Australia
IMUX Initiates Coverage On Wedbush -- Rating Set to Outperform - GuruFocus
Wedbush initiates Immunic stock with Outperform rating - Investing.com
Renaissance Technologies LLC Invests $1.02 Million in Immunic, Inc. $IMUX - MarketBeat
Immunic (NASDAQ:IMUX) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Immunic Inc. (IMUX) Pulls Back 3.14% to $16.06 as Key Support at $15.26 Comes into FocusCall Flow Alert - Vinanet
Immunic, Inc. (IMUX): OrbiMed entities disclose 5.3% and 2.8% equity holdings - Stock Titan
Nantahala Capital discloses 7.47% Immunic (IMUX) stake in Schedule 13G/A - Stock Titan
Immunic (IMUX): Commodore Capital discloses 9.9% stake capped by warrant limits - Stock Titan
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Immunic (IMUX) sees Soleus Capital group disclose 4.9% beneficial stake - Stock Titan
H.C. Wainwright Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Wolfe Research Maintains Immunic(IMUX.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Is Immunic Inc (IMUX) Struggling After Recent Earnings? EPS Misses Estimates with GF Score: 32/100 - GuruFocus
LifeSci Capital Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Small cap wrap: 1911 Gold, Dune Oil, Nextech3D.ai, C3 Metals, Immunic… - Proactive financial news
Immunic Releases Q2 2026 Financial Results - AlphaStreet
Immunic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Form 8K Immunic Inc For: 11 August By Investing.com - Investing.com Nigeria
Immunic (NASDAQ:IMUX) Issues Quarterly Earnings Results, Beats Estimates By $0.36 EPS - MarketBeat
Immunic Appoints Biopharma Finance Veteran Elena Ridloff to Board of Directors - Minichart
Immunic Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Immunic advances MS drug vidofludimus calcium t... - Pluang
Immunic posts investor presentation highlighting vidofludimus calcium Phase 3 MS program - Bitget
Immunic Inc Azioni (IMUX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):